Business Description
Xenon Pharmaceuticals Inc
NAICS : 325410
SIC : 3741
ISIN : CA98420N1050
Total Employee Number:
370Description
Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 145.01 | |||||
Equity-to-Asset | 0.96 | |||||
Debt-to-Equity | 0.01 | |||||
Debt-to-EBITDA | -0.02 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -15.2 | |||||
3-Year EBITDA Growth Rate | -30.4 | |||||
3-Year EPS without NRI Growth Rate | -29.8 | |||||
3-Year FCF Growth Rate | -27.2 | |||||
3-Year Book Growth Rate | -14.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 286.37 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 31.3 | |||||
9-Day RSI | 34.62 | |||||
14-Day RSI | 39.13 | |||||
3-1 Month Momentum % | 22.32 | |||||
6-1 Month Momentum % | 50.79 | |||||
12-1 Month Momentum % | 73.78 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 21.02 | |||||
Quick Ratio | 21.02 | |||||
Cash Ratio | 20.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -8.5 | |||||
Shareholder Yield % | -14.25 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -4547.67 | |||||
OCF Margin % | -4534.16 | |||||
ROE % | -46.97 | |||||
ROA % | -44.5 | |||||
ROIC % | -206.44 | |||||
3-Year ROIIC % | 340.43 | |||||
ROC (Joel Greenblatt) % | -2927.12 | |||||
ROCE % | -50.18 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 637.37 | |||||
PB Ratio | 4.72 | |||||
Price-to-Tangible-Book | 4.72 | |||||
EV-to-EBIT | -11.19 | |||||
EV-to-EBITDA | -11.25 | |||||
EV-to-Revenue | 658.59 | |||||
EV-to-Forward-Revenue | 1297.46 | |||||
EV-to-FCF | -14.59 | |||||
| Price-to-Net-Current-Asset-Value | 6.57 | |||||
| Price-to-Net-Cash | 6.68 | |||||
Earnings Yield (Greenblatt) % | -8.94 | |||||
FCF Yield % | -5.77 |
GF Valueâ„¢
Xenon Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Xenon Pharmaceuticals Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-03 16:30 | In 71 days | ||
| Third quarter earnings results for 2026 | 2026-11-03 | In 70 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 55.50 (+0.00%) | ||
| Second quarter earnings results for 2026 | 2026-08-06 | 55.50 (+0.00%) | ||
| Jeffries Global Healthcare Conference | 2026-06-04 09:55 | 45.80 (+2.69%) | ||
| General meeting for 2026 | 2026-06-02 09:30 | 45.80 (-2.14%) | ||
| First quarter earnings conference call for 2026 | 2026-05-07 16:30 | 50.00 (+1.63%) | ||
| First quarter earnings results for 2026 | 2026-05-07 | 50.00 (+1.63%) | ||
| Bloom Burton & Co. Healthcare Investor Conference | 2026-04-22 11:30 | 48.00 (-0.41%) | ||
| Phase 3 X-TOLE2 Study Topline Results | 2026-03-09 08:00 | 36.00 (+0.00%) |
Show
Entries
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Xenon Pharmaceuticals Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers